Key molecular markers such as HER-2, PRs and ERs and the Mib1/Ki-67 proliferation index are highly significant in the context of BC (BC) and undergo thorough validation in the routine care of both primary and recurrent, as well as metastatic BC patients [ 18 ].
← all excerpts
Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment.
1
—
—